权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Immunomodulatory biomaterial to enhancing T-cell responses to triple negative breast cancer

免疫调节生物材料可增强 T 细胞对三阴性乳腺癌的反应

基本信息

批准号：
10699815
负责人：
Fatemeh Sadat Majedi
金额：
$ 39.96万
依托单位：
SYMPHONY BIOSCIENCES, INC.
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-05-01 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10699815
关键词：
4T1 Abscopal effect Adjuvant Adverse effects Affect Alginates Antibodies Autoimmune Biocompatible Materials Biological Sciences Biomedical Engineering Biopsy Breast Cancer Model CAR T cell therapy Canis familiaris Caring Cells Certification Cessation of life Clinical Trials Cytotoxic T-Lymphocytes Data Development Devices Distant Distant Metastasis Drug Kinetics Early treatment Endowment Exons Flow Cytometry Formulation Funding Goals Hematologic Neoplasms Histology Human Immune Immune system Immunity Immunologics Immunotherapy Implant In Situ Incubators Infiltration LoxP-flanked allele Lymphocyte Lymphoma Malignant Neoplasms Mechanics Metastatic breast cancer Modality Mus Myelogenous Neoadjuvant Therapy Neoplasm Metastasis Operative Surgical Procedures Outcome Performance Phase Pilot Projects Porifera Rattus Regulatory T-Lymphocyte Secure Site Solid Neoplasm T cell response T-Cell Activation T-Lymphocyte Techniques Testing Time Toxic effect Transforming Growth Factor beta Translating Tumor Suppression United States Work arm biocompatible polymer biodegradable polymer cancer infiltrating T cells chemotherapy cytokine release syndrome design effector T cell engineered T cells exhaustion experience fighting immunoregulation improved inhibitor innovation lymph nodes malignant breast neoplasm manufacturability manufacture melanoma mouse model neoplastic cell novel therapeutics particle patient derived xenograft model polyoma middle tumor antigen pre-Investigational New Drug meeting recruit response scaffold side effect standard of care triple-negative invasive breast carcinoma tumor tumor microenvironment tumor-immune system interactions

项目摘要

Project Summary Deaths from solid tumors vastly outnumber deaths from hematopoietic cancers. Yet progress in immunotherapies for solid tumors is well behind those for lymphoma. CAR-T cell therapies and engineered T cells have become revolutionary approaches for hematopoietic cancers, but their potential for solid tumors is yet to be realized. Significant challenges hinder the potential of immune therapies in solid tumors, including insufficient activation and eventual exhaustion of effector T cells; and suppression of T cell effector responses in the tumor microenvironment. In this proposal we consider these hurdles and offer a biomaterial solution that overcomes them. This proposal is significant in facilitating endogenous T cells to fight solid tumors. Surgery is a major treatment modality for both invasive and in situ tumors, but at this time, there are no specific immunotherapies initiated at the time of surgery; they all start days to weeks later. Our proposal is significant for offering a way to start treatments early, right at the time of initial surgery. Here our synthetic scaffold, SymphNode can be injected at the time of biopsy or surgery not to only recruit and active tumor-experienced local immune cells but also to suppress the inhibitory cells created by tumor cells. Our long-term goal is to develop this bioengineered, locally injected, “synthetic lymph node” into a therapy for human tumors.

项目总结